High-resolution mapping of the polyclonal immune response to the human platelet alloantigen HPA-1a (PlA1)‏ by Huiying Zhi, Maria Therese Ahlen, Aye Myat.

Slides:



Advertisements
Similar presentations
Targeted Disruption of V600E-Mutant BRAF Gene by CRISPR-Cpf1
Advertisements

by S. Kangsadalampai, and P.G. Board
3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by.
Molecular characterization and expression of a novel human leukocyte cell-surface marker homologous to mouse Ly-9 by Miguel Angel de la Fuente, Victoria.
In vivo optimization of the tagging approach using the Act5C model locus and flow cytometry-based quantification of the Act5C-GFP tagging success. In vivo.
by Clemens B. Caspar, Shoshana Levy, and Ronald Levy
Integrin-linked kinase associated with integrin activation
Truncation of Glycoprotein (GP) IIIa (▵ ) Prevents Complex Formation With GPIIb: Novel Mutation in Exon 11 of GPIIIa Associated With Thrombasthenia.
A Point Mutation Thr799Met on the 2 Integrin Leads to the Formation of New Human Platelet Alloantigen Sita and Affects Collagen-Induced Aggregation by.
Superantigen Recognition by γδ T Cells
by David M. Weinstock, Beth Elliott, and Maria Jasin
CRISPR/Cas9-mediated genome editing of PML in human cell lines.
by Parisa Asvadi, Zohra Ahmadi, and Beng H. Chong
by Eun-Ju Lee, Daniel J. Dykas, Andrew D. Leavitt, Rodney M
A Three Amino Acid Deletion in Glycoprotein IIIa Is Responsible for Type I Glanzmann's Thrombasthenia: Importance of Residues Ile325Pro326Gly327 for β3.
Rose-Anne Romano, Barbara Birkaya, Satrajit Sinha 
Correction of a Genetic Disease in Mouse via Use of CRISPR-Cas9
Volume 31, Issue 1, Pages (July 2009)
Figure 1. Generation of the S250F Aadc mutant mice
Volume 9, Issue 3, Pages (November 2014)
Volume 10, Issue 5, Pages (November 2002)
Mouse Genome Engineering via CRISPR-Cas9 for Study of Immune Function
Volume 154, Issue 6, Pages (September 2013)
Volume 17, Issue 11, Pages (November 2009)
Volume 7, Issue 1, Pages (April 2014)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles
USH2A Gene Editing Using the CRISPR System
Hung-Ta Chen, Steven Hahn  Cell 
Molecular Therapy - Nucleic Acids
A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant by Shauna L. French, Claudia Thalmann, Paul F.
Rap1 binding to the talin 1 F0 domain makes a minimal contribution to murine platelet GPIIb-IIIa activation by Frederic Lagarrigue, Alexandre R. Gingras,
RNA-Guided Genome Editing in Plants Using a CRISPR–Cas System
Diabetes Mutations Delineate an Atypical POU Domain in HNF-1α
Volume 154, Issue 6, Pages (September 2013)
Volume 153, Issue 4, Pages (May 2013)
Selective Dimerization of a C2H2 Zinc Finger Subfamily
BRCA2 Is Required for Homology-Directed Repair of Chromosomal Breaks
RAD51 is essential for L. donovani.
Gang Wang, Na Zhao, Ben Berkhout, Atze T Das  Molecular Therapy 
Targeted Myostatin Gene Editing in Multiple Mammalian Species Directed by a Single Pair of TALE Nucleases  Li Xu, Piming Zhao, Andrew Mariano, Renzhi.
GFP to BFP Conversion: A Versatile Assay for the Quantification of CRISPR/Cas9- mediated Genome Editing  Astrid Glaser, Bradley McColl, Jim Vadolas  Molecular.
The Basis for IL-2-Induced IL-2 Receptor α Chain Gene Regulation
William T. Hendriks, Curtis R. Warren, Chad A. Cowan  Cell Stem Cell 
Volume 2, Issue 1, Pages (July 1998)
Volume 153, Issue 4, Pages (May 2013)
Molecular Therapy - Nucleic Acids
Mutagenesis through Cas9/sgRNA-induced HDR
Molecular Therapy - Nucleic Acids
Volume 7, Issue 6, Pages (December 1997)
Volume 52, Issue 3, Pages (November 2013)
Tagging of the endogenous Py03652 gene with the gfp gene in Plasmodium yoelii. Tagging of the endogenous Py03652 gene with the gfp gene in Plasmodium yoelii.
Figure 1. Ability of fluconazole to improve survival of G
Transcriptional Control of SLC26A4 Is Involved in Pendred Syndrome and Nonsyndromic Enlargement of Vestibular Aqueduct (DFNB4)  Tao Yang, Hilmar Vidarsson,
Generation of heterozygous mutations with the CRISPR-Cas9 system.
Volume 15, Issue 2, Pages (August 2014)
Volume 16, Issue 2, Pages (February 2015)
The sh339 and qmc554 alleles of gfi1b.
Fig. 4 Gene disruption via chip.
Exome Sequencing Identifies CCDC8 Mutations in 3-M Syndrome, Suggesting that CCDC8 Contributes in a Pathway with CUL7 and OBSL1 to Control Human Growth 
Expression of multiple forms of MEL1 gene products.
VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites by Katrin J. Czogalla, Kerstin Liphardt,
Volume 9, Issue 4, Pages (April 2016)
by Pan Tao, Xiaorong Wu, and Venigalla Rao
CRISPR Immunological Memory Requires a Host Factor for Specificity
Volume 25, Issue 4, Pages e3 (October 2018)
Genome-Edited Triple-Recessive Mutation Alters Seed Dormancy in Wheat
Potent and sequence-specific removal through genome targeting with CRISPR-Cas systems. Potent and sequence-specific removal through genome targeting with.
Knock-in of the rpl42-P56Q mutation using the split-ura4 system.
Presentation transcript:

High-resolution mapping of the polyclonal immune response to the human platelet alloantigen HPA-1a (PlA1)‏ by Huiying Zhi, Maria Therese Ahlen, Aye Myat Myat Thinn, Hartmut Weiler, Brian R. Curtis, Bjørn Skogen, Jieqing Zhu, and Peter J. Newman BloodAdv Volume 2(21):3001-3011 November 13, 2018 © 2018 by The American Society of Hematology

Huiying Zhi et al. Blood Adv 2018;2:3001-3011 © 2018 by The American Society of Hematology

Three-dimensional structure of the human GPIIIa PSI and EGF1 domains. Three-dimensional structure of the human GPIIIa PSI and EGF1 domains. (A) Note that the PSI domain lies between the hybrid and EGF1 domains of GPIIIa and that polymorphic amino acid 33, which controls expression of the HPA-1a (PlA1) epitope, is directly opposite the linearly distant but conformationally close EFG1 domain. (B) Mutation to alanine of Cys435, which links the EGF1 domain to the PSI domain via a disulfide bond with Cys13, has previously been shown to result in the loss of binding of some, but not all, maternal anti–HPA-1a alloantibodies, leading to speculation that nonpolymorphic amino acids in EGF1 constitute part of the epitope for these so-called type II antibodies. Huiying Zhi et al. Blood Adv 2018;2:3001-3011 © 2018 by The American Society of Hematology

CRISPR-mediated generation of the APLD humanized transgenic mouse. CRISPR-mediated generation of the APLD humanized transgenic mouse. (A) Three-dimensional structure of the GPIIIa PSI domain, showing the location of the residues that were mutated in the murine protein to humanize the 22 to 40 amino acid loop. (B) Schematic illustration of the ITGB3 locus, showing the location of the gRNA binding site (red bar), the protospacer adjacent motif (PAM) sequence (magenta bar), and the Cas9 cleavage site (red arrow heads). A 200-bp APLD homology directed repair (HDR) template was designed to introduce the 4 desired amino acid substitutions (mutated nucleotides labeled in red) and a diagnostic BamH1 restriction site (silent mutation nucleotides labeled in blue) flanked by 80 nucleotide homology arms. The HDR template also introduces nucleotides (green) that encode silent mutations to prevent recleavage by Cas9. (C) The 20-bp gRNA shown in panel B, designed to target the Cas9 nuclease to the ITGB3 gene, was cloned into the BbsI site of the CRISPR vector px459, which also encodes both Cas9 and a puromycin-resistance gene. Pronuclei of C57BL/6N fertilized eggs were microinjected with the px459 plasmid along with the HDR template to generate the humanized APLD mouse. (D) PCR strategy designed to report the incorporation of the HDR template within a 717-bp region surrounding the targeted site of the murine ITGB3 gene. The introduced BamH1 is marked by a blue box. (E) Genotyping of 2 representative pups. Genomic DNA from the pups’ tails was PCR amplified and digested with BamH1 to identify correctly targeted APLD alleles. The PCR product of pup 1 cut with BamH1, demonstrating successful incorporation of the HDR oligo. The arrows indicate the expected BamH1 digestion products. (F) The ITGB3 locus surrounding the genomic editing site was PCR amplified from genomic DNA of pup 1 and subjected to DNA sequence analysis, confirming precise homozygous integration of the human sequence into both alleles of murine ITGB3. Huiying Zhi et al. Blood Adv 2018;2:3001-3011 © 2018 by The American Society of Hematology

The APLD humanized murine PSI domain supports the binding of many, but not all, human anti–HPA-1a alloantisera. The APLD humanized murine PSI domain supports the binding of many, but not all, human anti–HPA-1a alloantisera. (A) Flow cytometric analysis of the binding of the HPA-1a–selective murine mAb SZ21 to human and mouse platelets. Note that SZ21 binds to human HPA-1a+ but not HPA-1b+ human platelets, demonstrating its alloselectivity, and to APLD but not WT murine platelets. The PSI domain–specific mAb PSIB1 was used as a positive control for expression of GPIIb-IIIa and, as shown, binds all PSI domains, regardless of species or HPA allotype. (B) Antigen capture enzyme-linked immunosorbent assay of anti–HPA-1a maternal alloantisera binding to human and murine forms of GPIIb-IIIa. Five different human FNAIT alloantisera were incubated with human or murine platelet of the indicated phenotype. Platelet/antibody complexes were then detergent lysed and added to microtiter wells that had been coated with either anti-mouse CD41 to capture immune complexes from mouse platelets or mAb AP2 to capture immune complexes from human platelets. Note that human alloantisera 2, 3, and 4 react similarly with human GPIIb-IIIa and APLD murine GPIIb-IIIa, whereas alloantisera 1 and 5 do not react with murine APLD GPIIb-IIIa, suggesting that the preponderance of the HPA-1a–specific alloantibodies present in these polyclonal sera have more complex epitope requirements. None of the FNAIT alloantisera react with WT murine GPIIb-IIIa, as expected. Huiying Zhi et al. Blood Adv 2018;2:3001-3011 © 2018 by The American Society of Hematology

Structural requirements for binding of type II anti–HPA-1a antibodies. Structural requirements for binding of type II anti–HPA-1a antibodies. (A) Flow cytometric analysis of the reactivity of HPA-1a–specific mAbs with human and mouse platelets. Platelets from the indicated species and having the indicated phenotypes were reacted with mAbs SZ21, 26.4, and B2G1. Note that the type II mAb 26.4 requires that muGPIIIa be humanized from Met to Gln at residue 470 of the EGF1 domain, which is spatially close to the PSI domain, as depicted in panel B. Another type II HPA-1a–specific mAb, B2G1, remains unreactive with APLDQ platelets, highlighting the complexity of binding specificities that are likely present in the polyclonal humoral response to the Leu33Pro polymorphism that controls formation of the HPA-1a epitope. Huiying Zhi et al. Blood Adv 2018;2:3001-3011 © 2018 by The American Society of Hematology

Multiple amino acids within I-EGF1 can contribute to the binding of type II anti–HPA-1a antibodies. Multiple amino acids within I-EGF1 can contribute to the binding of type II anti–HPA-1a antibodies. (A) Comparison of human vs murine PSI and I-EGF1 domain sequences, with differences highlighted in red. Note especially the APLD sequences in the PSI domain and the Q470M, H446P, G463D, and P464Q differences within EGF1. (B) Structural model of the variable region of antibody B2G1 bound with the β3 PSI and I-EGF1 domains. The antibody is shown as a tan surface with the CDR loops indicated, and the side chains of integrin β3 residues at the antigen-antibody interface are shown as sticks and dots. Note that interface interacting residues include not only polymorphic amino acid 33 but also P32 in the PSI domain and H446 and Q470 of I-EGF1. Also note that G463 and P464 are nowhere near the interface. (C) Top: HEK 293 cells transiently transfected with plasmids expressing human GPIIb and a muGPIIIa isoform that had been mutated to express the indicated humanized amino acid substitution were incubated with the indicated antibodies and subjected to flow cytometric analysis. The PSI domain–specific mAb PSIB1 was used as a control for transfection efficiency. Note that mAb 26.4 requires Q470 for its binding, whereas B2G1 requires both Q470 and H446, as predicted in the docking model in panel B. Bottom: HEK 293 cells transfected with plasmids expressing human GPIIb and a human GPIIIa isoform that had been mutated to express the indicated mouse amino acids were subjected to flow cytometric analysis using the indicated antibodies. Note that the Q470→M mutation results in loss of binding of both 26.4 and B2G1, whereas the H446→P amino acid substitution affects only B2G1. Huiying Zhi et al. Blood Adv 2018;2:3001-3011 © 2018 by The American Society of Hematology